Results from the phase 2 RESONATE™-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

被引：0

作者：

Stilgenbauer, S. ^{[1
]}

Jones, J. A. ^{[2
]}

Coutre, S. E. ^{[3
]}

Mato, A. R. ^{[4
]}

Hillmen, P. ^{[5
]}

Tam, C. ^{[6
]}

Osterborg, A. ^{[7
]}

Siddiqi, T. ^{[8
]}

Thirman, M. J. ^{[9
]}

Furman, R. R. ^{[10
]}

Ilhan, O. ^{[11
]}

Keating, M. ^{[12
]}

Call, T. G. ^{[13
]}

Brown, J. R. ^{[14
]}

Stevens-Brogan, M. ^{[15
]}

Li, Y. ^{[15
]}

Clow, F. ^{[15
]}

James, D. F. ^{[15
]}

Chu, A. D. ^{[15
]}

Hallek, M. ^{[16
,17
]}

O'Brien, S. ^{[12
]}

机构：

[1] Univ Ulm, D-89069 Ulm, Germany

[2] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

[3] Stanford Univ, Sch Med, Div Hematol, Stanford Canc Ctr, Stanford, CA 94305 USA

[4] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[5] Leeds Teaching Hosp, St James Inst Onco, Leeds, W Yorkshire, England

[6] Peter MacCallum Canc Ctr, East Melbourne, Australia

[7] Karolinska Univ Hosp Solna, Dept Hematol, Solna, Sweden

[8] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[9] Univ Chicago Med, Hematol Oncol Sect, Chicago, IL USA

[10] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA

[11] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[13] Mayo Clin, Div Hematol, Rochester, MN USA

[14] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA

[15] Pharmacyclics Inc, Sunnyvale, CA USA

[16] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[17] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V291

引用

页码：92 / 92

页数：1

共 50 条

[21] Results From the Phase 3 DUO Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 4 - 5
[22] Results from the Phase 3 DUOTM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Flinn, Ian W.
Hillmen, Peter
Montillo, Marco
Nagy, Zsolt
Illes, Arpad
Etienne, Gabriel
Delgado, Julio
Kuss, Bryone Jean
Tam, Constantine S.
Gasztonyi, Zoltan
Offner, Fritz
Lunin, Scott D.
Bosch, Francesco
Davids, Matthew S.
Lamanna, Nicole
Jaeger, Ulrich
Ghia, Paolo
Cymbalista, Florence
Portell, Craig A.
Skarbnik, Alan P.
Cashen, Amanda
Kelly, Virginia
Turnbull, Barry
Stilgenbauer, Stephan
BLOOD, 2017, 130
[23] RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL
Hillmen, P.
Brown, J. R.
O'Brien, S.
Barrientos, J.
Kay, N. E.
Reddy, N. M.
Coutre, S.
Tam, C.
Mulligan, S.
Jaeger, U.
Devereux, S.
Barr, P. M.
Furman, R.
Kipps, T.
Cymbalista, F.
Pocock, C.
Thornton, P.
Caligaris-Cappio, F.
Robak, T.
Delgado, J.
Schuster, S. J.
Montillo, M.
Schuh, A.
DeVos, S.
Gill, D.
Bloor, A.
Dearden, C.
Moreno, C.
Jones, J. J.
Chu, A. D.
Fardis, M.
McGreivy, J.
Clow, F.
James, D.
Byrd, J. C.
HAEMATOLOGICA, 2014, 99 : 244 - 244
[24] A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Long, Meixiao
Woyach, Jennifer
Pinilla-Ibarz, Javier
Stephens, Deborah M.
Cacovean, Alex
Fiaz, Rana
Goldberg, Zelanna
Jagasia, Madan
Finckenstein, Friedrich Graf
Fardis, Maria
Byrd, C.
CANCER RESEARCH, 2021, 81 (13)
[25] TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel in Combination With Ibrutinib for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 19
[26] Updated efficacy including subgroup analyses and safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma
Dearden, C.
Brown, J. R.
Hillmen, P.
O'Brien, S.
Barrientos, J. C.
Reddy, N. M.
Coutre, S.
Tam, C. S.
Mulligan, S.
Jaeger, U.
Barr, P. M.
Furman, R. R.
Kipps, T. J.
Cymbalista, F.
Caligaris-Cappio, F.
Delgado, J.
Montillo, M.
DeVos, S.
Moreno, C.
Pagel, J.
Burger, J.
Chung, D.
Lin, J.
Gau, L.
Chang, B.
James, D.
Byrd, J.
Thornton, P.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 19 - 20
[27] Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Brown, Jennifer R.
Hillmen, Peter
O'Brien, Susan
Barrientos, Jaqueline C.
Reddy, Nishitha
Coutre, Steven
Tam, Constantine
Mulligan, Stephen
Jaeger, Ulrich
Barr, Paul M.
Furman, Richard R.
Kipps, Thomas J.
Cymbalista, Florence
Thornton, Patrick
Caligaris-Cappio, Federico
Delgado, Julio
Montillo, Marco
Devos, Sven
Moreno, Carol
Pagel, John
Burger, Jan A.
Chung, Devon
Lin, Jennifer
Gau, Linda
Chang, Betty
McGreivy, Jesse
James, Danelle F.
Byrd, John C.
BLOOD, 2014, 124 (21)
[28] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Song, Yuqin
Zhou, Keshu
Yang, Shenmiao
Hu, Jianda
Zou, Dehui
Gao, Sujun
Pan, Ling
Wang, Tingyu
Yang, Haiyan
Zhang, Huilai
Zhou, Daobin
Ji, Jie
Xu, Wei
Feng, Ru
Jin, Jie
Lv, Fangfang
Huang, Haiwen
Fan, Xiaosi
Xu, Sheng
Zhu, Jun
INVESTIGATIONAL NEW DRUGS, 2023, 41 (04) : 606 - 616
[29] Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
Brown, J. Jennifer R.
Byrd, John C.
O'Brien, Susan
Barrientos, Jacqueline C.
Kay, Neil E.
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine S.
Mulligan, Stephen
Jaeger, Ulrich
Devereux, Stephen
Barr, Paul M.
Furman, Richard
Kipps, Thomas
Cymbalista, Florence
Fardis, Maria
McGreivy, Jesse
Clow, Fong
James, Danelle F.
Hilmen, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S204
[30] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Yuqin Song
Keshu Zhou
Shenmiao Yang
Jianda Hu
Dehui Zou
Sujun Gao
Ling Pan
Tingyu Wang
Haiyan Yang
Huilai Zhang
Daobin Zhou
Jie Ji
Wei Xu
Ru Feng
Jie Jin
Fangfang Lv
Haiwen Huang
Xiaosi Fan
Sheng Xu
Jun Zhu
Investigational New Drugs, 2023, 41 : 606 - 616

← 1 2 3 4 5 →